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Abstract: Epigenetic silencing of protein-encoding genes is common in early-stage colorectal tumorigen-
esis. Less is known about the methylation-mediated silencing of genes encoding microRNAs (miRNAs),
which are also important epigenetic modulators of gene expression. Using quantitative PCR, we iden-
tified 56 miRNAs that were expressed in normal colorectal mucosa and in HT29 colorectal cancer cells
treated with demethylating agents but not in untreated HT29 cells, suggesting that they probably un-
dergo methylation-induced silencing during colorectal tumorigenesis. One of these, miR-195, had recently
been reported to be underexpressed in colorectal cancers and to exert tumor-suppressor effects in colorec-
tal cancer cells. We identified the transcription start site (TSS) for primary miRNA (pri-miR)-497/195,
the primary precursor that yields miR-195 and another candidate on our list, miR-497, and a single CpG
island upstream to the TSS, which controls expression of both miRNAs. Combined bisulfite restriction
analysis and bisulfite genomic sequencing studies revealed monoallelic methylation of this island in nor-
mal colorectal mucosa (50/50 samples) and full methylation in most colorectal adenomas (38/50; 76%).
The hypermethylated precancerous lesions displayed significantly downregulated expression of both miR-
NAs. Similar methylation patterns were observed at two known imprinted genes, MEG3 and GNAS-AS1,
which encode several of the 56 miRNAs on our list. Imprinting at these loci was lost in over half the
adenomas (62% at MEG3 and 52% at GNAS-AS1). Copy-number alterations at MEG3, GNAS-AS1 and
pri-miR-497/195, which are frequent in colorectal cancers, were less common in adenomas and confined
to tumors displaying differential methylation at the involved locus. Our data show that somatically ac-
quired, epigenetic changes at monoallelically methylated regions encoding miRNAs are relatively frequent
in sporadic colorectal adenomas and might contribute to the onset and progression of these tumors.
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Epigenetic silencing of protein-encoding genes is common in early-stage colorectal tumorigenesis. Less is known about the
methylation-mediated silencing of genes encoding microRNAs (miRNAs), which are also important epigenetic modulators of gene
expression. Using quantitative PCR, we identified 56 miRNAs that were expressed in normal colorectal mucosa and in HT29
colorectal cancer cells treated with demethylating agents but not in untreated HT29 cells, suggesting that they probably undergo
methylation-induced silencing during colorectal tumorigenesis. One of these, miR-195, had recently been reported to be
underexpressed in colorectal cancers and to exert tumor-suppressor effects in colorectal cancer cells. We identified the
transcription start site (TSS) for primary miRNA (pri-miR)-497/195, the primary precursor that yields miR-195 and another candidate
on our list, miR-497, and a single CpG island upstream to the TSS, which controls expression of both miRNAs. Combined bisulfite
restriction analysis and bisulfite genomic sequencing studies revealed monoallelic methylation of this island in normal colorectal
mucosa (50/50 samples) and full methylation in most colorectal adenomas (38/50; 76%). The hypermethylated precancerous lesions
displayed significantly downregulated expression of both miRNAs. Similar methylation patterns were observed at two known
imprinted genes, MEG3 and GNAS-AS1, which encode several of the 56 miRNAs on our list. Imprinting at these loci was lost in over
half the adenomas (62% at MEG3 and 52% at GNAS-AS1). Copy-number alterations at MEG3, GNAS-AS1 and pri-miR-497/195, which
are frequent in colorectal cancers, were less common in adenomas and confined to tumors displaying differential methylation at
the involved locus. Our data show that somatically acquired, epigenetic changes at monoallelically methylated regions encoding
miRNAs are relatively frequent in sporadic colorectal adenomas and might contribute to the onset and progression of these tumors.
Oncogenesis (2013) 2, e56; doi:10.1038/oncsis.2013.21; published online 15 July 2013
Subject Categories: Molecular oncology
Keywords: miR-497; miR-195; CpG-island methylation; allele-specific DNA methylation
INTRODUCTION
Discovered almost 30 years ago,1 cancer-related epigenetic alterations
in gene expression patterns have now been found in almost every
component of human chromatin.2 The most widely studied changes
of this type involve DNA methylation at CpG dinucleotides, which can
affect the expression of protein-coding genes and noncoding
RNAs, such as microRNAs (miRNAs).3 The latter bind to messenger
RNAs (mRNAs) with base-pair sequences more or less complementary
to their own, causing degradation of the target transcript or
repressing its translation.4 miRNAs are believed to regulate the
translation of over 60% of all protein-coding genes,5 including many
known oncogenes and tumor suppressors.6 Epigenetic silencing of
protein-encoding genes is a well-documented feature of colorectal
tumorigenesis,7–10 but less is known about the epigenetic regulation
of miRNA genes in this setting.
We recently screened 742 human miRNAs to identify those
whose expression in the colon might be silenced by DNA
methylation during the course of malignant transformation.
Unexpectedly, the candidates that emerged included several
miRNA genes that were monoallelically methylated in normal
colorectal mucosa, including some located in imprinted loci of the
genome. The parent-of-origin-specific monoallelic expression that
characterizes imprinting11 has crucial roles in normal growth and
development.12 Genetic and/or epigenetic alterations can activate
the normally silenced allele or silence the one that is normally
expressed,13 and this loss of imprinting (LOI) has been described
in several types of cancer.14 To date, B80 imprinted human genes
have been identified (http://www.geneimprint.com/), but
bioinformatic predictions indicate that the true number is
probably higher.11,15 Allele-specific DNA methylation (ASM) of
nonimprinted genes also seems to be widespread in the human
genome,16 and loci of this type are also potential targets of
epigenetic changes relevant for tumorigenesis.
Here, we show that a single CpG island controls the expression
of two miRNAs, miR-497 and miR-195, which appear to undergo
silencing during colorectal tumorigenesis. In normal colorectal
mucosa, this island was found to be monoallelically methylated,
but in precancerous colorectal lesions, biallelic methylation was
more common, a pattern similar to that observed at the CpG
islands of two other multi-miRNA-encoding loci (MEG3 and GNAS-
AS1), which are known to be imprinted.
RESULTS
Using quantitative real-time PCR (qPCR), we measured the levels
of 742 human miRNAs in HT29 colorectal cancer cells before and
1Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland; 2Gastroenterology and Endoscopy Unit, Hospital of Cremona, Cremona, Italy; 3Gastroenterology
and Endoscopy Unit, University of Zurich Hospital, Zurich, Switzerland and 4Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland. Correspondence:
Professor G Marra, Institute of Molecular Cancer Research, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
E-mail: marra@imcr.uzh.ch
Received 5 April 2013; revised 10 May 2013; accepted 15 May 2013
Citation: Oncogenesis (2013) 2, e56; doi:10.1038/oncsis.2013.21
& 2013 Macmillan Publishers Limited All rights reserved 2157-9024/13
www.nature.com/oncsis
after treatment with the DNA-demethylating agent 5-aza-2-
deoxycytidine and the histone deacetylase inhibitor trichostatin
A and in a single sample of normal colonic mucosa. Fifty-six
miRNA genes had expression patterns suggestive of methylation-
induced silencing during colorectal tumorigenesis, that is,
constitutive expression in normal mucosa, loss of expression in
HT29 cells and restored expression in HT29 cells treated with
5-aza-2-deoxycytidine/trichostatin A (Table 1, left column).
Shortly after we completed these experiments, one of the
candidate miRNAs, miR-195, was reported to be underexpressed in
colorectal cancers (73% of the 81 carcinomas analyzed) and to exert
tumor-suppressor activity in HT29 and LoVo colon cancer cells
involving the reduction of BCL2 levels.17 These findings, along with
reports of miR-195-induced tumor suppression in hepatocellular,18,19
adrenocortical20 and peritoneal tumorigenesis,21 prompted us to
investigate the mechanism underlying miR-195 downregulation
during colorectal tumorigenesis.
Given the criteria used in our screening study, the most likely
cause seemed to be cytosine methylation at CpG island(s) in the
miR-195 promoter region. MiR-195 and miR-497, another miRNA
gene that appeared to be epigenetically silenced during
colorectal-cell transformation (Table 1), are both encoded in the
first intron of the MIR497HG gene (Gene ID: 100506755) on
chromosome 17p13.1. The transcription start site (TSS) for the
primary precursor that yields both these miRNAs (primary miRNA
(pri-miR)-497/195) had not been identified, but it was predicted to
be independent of its host-gene promoter.22,23 We identified this
site by subjecting total RNA from the normal mucosa specimen to
rapid amplification of cDNA ends (5’ RACE) (Figure 1a) and
explored a CpG island flanking this site as a potential target of
cytosine methylation (Figure 1b).
Using combined bisulfite restriction analysis (COBRA), we
investigated the methylation status of this island in HT29 cells
and five other colorectal cancer lines and in 50 paired adenoma-
normal mucosa samples (Table 2). The extensive methylation of
this island documented in all six cell lines (Figure 1c) suggests that
this phenomenon is quite common in advanced colorectal cancers
with different genetic and epigenetic backgrounds and/or in
cultured cells in general. In all 50 samples of normal mucosa
(controls), methylation of this CpG island was observed in roughly
half of the alleles (see representative example in Figure 1c). The
presence of methylated and unmethylated alleles in these
samples might have reflected differences between the epithelial
and mesenchymal components of the mucosa, as described for
miR-200b.24 To explore this possibility, we isolated lamina propria
and epithelial crypts from a single surgical specimen of normal
mucosa and subjected the DNA from each tissue component to
COBRA. Both contained methylated and unmethylated pri-miR-
497/195 alleles (Figure 1d). RT–PCR confirmed the purity of the
isolated tissue components and the presence in both of miR-497
and miR-195 (although they were more abundantly expressed in
the lamina propria) (Figure 1e).
As for the 50 colorectal adenomas, 38 (76%) exhibited extensive
methylation of pri-miR-497/195 alleles. Representative COBRA
experiments are shown in Figure 2a. In the remaining 12 (24%),
pri-miR-497/195 allele methylation resembled that observed in
the corresponding samples of normal mucosa (for example,
the one shown for patient 9 in Figure 2a). A similar picture
emerged when subcloned PCR products of bisulfite-converted
DNA from these tissues were sequenced: heavy methylation was
observed in almost all the pri-miR-497/195 alleles in adenomas
but in only B50% of those in the normal mucosal specimens
(Figure 2b).
Using RT–PCR, we compared miR-497 and miR-195 expression in
five adenomas with hypermethylation at pri-miR-497/195 and five
others with methylation levels at this locus comparable to those in
the normal mucosal samples. The significantly lower transcript
levels of both mRNAs found in the hypermethylated tumors
(Figure 2c) support our view that the CpG island we analyzed has a
role in the epigenetic control of miR-497/195 cluster transcription.
The asymmetric methylation of this island observed in normal
mucosal DNA was suggestive of genomic imprinting, a phenom-
enon known to affect loci encoding several miRNAs listed in
Table 1. We examined the monoallelically methylated CpG islands
of two of these imprinted loci in DNA from our paired adenoma-
normal mucosa samples: GNAS-AS1, which encodes miR-296,25,26
Table 1. MicroRNAs that were re-expressed in HT29 cells after





























































Boldface represents miRNA cluster in chromosome 14q32 (MEG3 locus).
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and MEG3, which encodes 16 miRNAs in our list.27,28 The results
recalled those obtained for pri-miR-497/195 CpG island.
Methylated and unmethylated alleles of GNAS-AS1 and MEG3
were found in all 50 specimens of normal mucosa, whereas
methylated alleles of both loci predominated in most adenomas
(Figures 3a and b), reflecting tumor-related LOI. Twenty-six (52%)
of the 50 adenomas presented LOI at GNAS-AS1 (involving
hypermethylation of the active allele in 24 and hypomethylation
of the silenced allele in 2). LOI at MEG3 was even more common:
hypermethylation of this locus was documented in 31 (62%) of the
adenomas.
RT–PCR confirmed that miR-296-5p expression was significantly
downregulated in adenomas with LOI at GNAS-AS1 (Figure 3a). For
the MEG3 locus, which encodes over 50 miRNAs,29 we limited our
analysis to three of those that appeared to undergo epigenetic
silencing during colorectal tumorigenesis (Table 1). As shown in
Figure 3b, two of these, miR-127-3p and miR-154, displayed
underexpression (statistically significant in the latter case) in the
adenomas with LOI at MEG3, whereas the third, miR-495, was
slightly but not significantly overexpressed in these tumors.
Collectively, these data suggest that pri-miR-497/195 is—like
GNAS-AS1 and MEG3—an imprinted locus, and that imprinting at
all three loci is frequently lost during colorectal tumorigenesis. As
shown in Figure 4, 20 (40%) of the 50 adenomas we examined
exhibited hypermethylation at all three loci, and 12 others (24%)
were methylated at two of the three. Only seven adenomas (14%)
exhibited methylation at all three loci that was similar to that of
their paired samples of normal mucosa.
LOI can also stem—wholly or in part—from genetic events,
such as copy-number alterations (CNAs). Using qPCR, we assessed
CNA frequencies at GNAS-AS1 (chromosome 20q13.3), MEG3
(14q32) and pri-miR-497/195 (17p13.1) in our 50 adenomas. As
reported in Figure 4, nine of the tumors presented amplifications,
which involved GNAS-AS1 in seven tumors, pri-miR-497/195 in one
and MEG3 in another. Deletions were found at pri-miR-497/195 in
four adenomas and at MEG3 in one. Interestingly, all the CNAs
were found in adenomas with COBRA-documented differential
methylation of the involved locus (compared with normal mucosa
from the same patient), including the two that appeared to be






































































Figure 1. Identification of the pri-miR-497/195 TSS in normal human colorectal mucosa and assessment of the methylation status of the CpG
island located upstream from this site. (a) 50 RACE: a 3638-bp product was obtained by nested PCR with the gene-specific outer and inner
primers listed in Material and methods. (b) Schematic showing locations of miR-497 and miR-195, the pri-miR-497/195 TSS and the CpG island
located upstream from the latter (genome coordinates of pri-miR-497/195 from its TSS tomiR-497 according to the Human Reference Sequence
GRCh37/hg19: chr17, 6 921 342–6 924 948). The position of the 294-bp COBRA amplicon is 6 926 487–6 926 780. (c) COBRA analysis of six
colorectal cancer cell lines and a control sample of normal colon mucosa. Arrows indicate TaqaI-digested DNA fragments representing
methylated alleles; slower-migrating fragments represent undigested, unmethylated DNA. (d) COBRA revealed methylated and unmethylated
pri-miR-497/195 alleles in isolated epithelial cells and isolated stromal (lamina propria) cells from the normal mucosa. (e) Left panel: the purity
of the epithelial cell preparation was confirmed by qPCR exclusion of the expression of Vimentin, a stromal marker that was abundant in the
lamina propria specimens. Right panel: RT–PCR revealed higher expression of miR-195 and miR-497 in the stromal component.
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This is the first evidence suggesting that the pri-miR-497/195
locus might be imprinted in colorectal tissues. To validate this
hypothesis in our colorectal tissue samples, we analyzed the
transcribed pri-miR-497/195 sequence identified by 5’ RACE for
single-nucleotide polymorphisms (SNPs) that could be employed
to distinguish alleles. Unfortunately, the only candidate that
emerged, SNP rs412999 (dbSNP ID: 412999), is extremely rare in
individuals of northern and western European ancestry (CEU
samples of The HapMap 3 collection) and was therefore unsuitable
for use in our tissue series. As an alternative, we sequenced RNA
from B-lymphocytes from three Nigerian individuals known to be
heterozygous for this SNP, but as shown in Supplementary
Table 1, none of the samples exhibited any evidence of
preferential allelic expression.
Our final set of experiments focused on putative or validated
mRNA targets of miR-497 and miR-195 identified in public
databases (mirTarBase,30 miRecords31 and miRWalk32). In a data
set previously collected by our group,33 35 of these mRNAs had
presented significantly upregulated expression in precancerous
colorectal lesions (relative to normal mucosa samples from the
Table 2. Characteristics of the 50 patients with precancerous colorectal lesions included in the study
Patient
no.










Dysplasiad No. of lesions
presente
1 F 75 Tra 20 IIa IIIS-IIIL VA High 7
2 F 75 Tra 40 IIa-IIc IIIS-IIIL TA High 1
3 F 54 Cec 45 IIa IIIL TVA Low 16
4 M 73 Asc 30 Is nr TVA High 1
5 F 69 Asc 45 Ip nr TVA high 1
6 M 74 Rec 40 Is IV VA high 2
7 M 80 Asc 40 IIa IIIL TVA Low 1
8 M 77 Cec 25 IIa IIIL VA Low 1
9 M 71 Sig 30 IIa IIIL TVA Low 2
10 M 89 Rec 30 Is IV TA Low 3
11 F 85 Sig 25 Is-IIa IV TA Low 1
12 F 63 Sig 35 Ip IV VA Low 1
13 M 82 Asc 15 IIa IIIL VA Low 2
14 F 73 Asc 25 IIa-IIc IIIs-IIIL TA Low 1
15 F 70 Cec 25 IIa IIIL TVA Low 2
16 M 70 Asc 15 Is IV TVA Low 7
17 M 63 Asc 45 Is IIIL-IV TVA Low 1
18 F 73 Sig 20 Ip IV TVA Low 1
19 M 60 Des 30 Is IV-Vi TVA High 1
20 M 68 Asc 30 Is-IIa IIIL-IV TVA High 1
21 M 55 Cec 25 Is-IIa IIIL-IV SSA Low 1
22 M 64 Sig 12 Ip IIIL TA Low 1
23 M 78 Asc 50 Is IV-Vi TA Low 1
24 F 69 Rec 90 Is-IIa IV TVA Low 1
25 F 78 Rec 60 Is-IIa IV TVA Low 1
26 M 72 Asc 30 Is IV TVA High 2
27 M 76 Sig 30 Is IV-Vi TA High 1
28 M 75 Rec 25 Is IV-Vn TVA High 6
29 M 66 Asc 30 IIa IIIL TA High 2
30 F 66 Asc 30 Is-IIa IV TA High 2
31 M 75 Tra 18 IIa IIIL TA Low 1
32 M 61 Asc 40 Is-IIa IV TVA Low 20
33 M 84 Cec 30 Is Vn TVA High 1
34 M 59 Tra 30 IIa-IIc IIIs-IIIL TA Low 1
35 F 73 Rec 50 Is IV VA Low 1
36 F 73 Des 25 Is IV TA Low 1
37 M 59 Rec 60 Is IV-Vi TVA High 1
38 M 75 Asc 40 IIa II TA Low 6
39 M 75 Asc 50 Is Vn TVA High 7
40 M 77 Sig 25 IIa-IIc IIIs-IIIL TA Low 1
41 F 72 Asc 20 Is IV TVA Low 1
42 F 66 Sig 35 Ip IV TA Low 1
43 F 78 Rec 45 Ip IV TVA High 1
44 M 74 Sig 25 Ip IIIs-IV TA Low 1
45 M 60 Cec 30 Is IV TVA Low 2
46 M 62 Des 22 Ip nr TA Low 1
47 F 68 Asc 16 IIa nr TA High 1
48 F 46 Des 30 Ip nr TVA High 2
49 M 75 Cec 20 Is nr TVA Low 1
50 M 59 Sig 8 Ip nr TA Low 2
aAbbreviations: Asc, ascending colon; Cec, cecum; Des, descending colon; nr, pit pattern not reported by the endoscopist; Rec, rectum; Sig, sigma; SSA, sessile
serrated adenoma; TA, tubular adenoma; Tra, transversum; TVA, tubulovillous adenoma; VA, villous adenoma. bClassified according to the Paris Endoscopic
Classification of Superficial Neoplastic Lesions.60 cKudo classification of colonic crypt morphology.61 dHighest degree of dysplasia in the lesion based on the
WHO classification of tumors of the digestive system.62 eTotal number of lesions noted during the study colonoscopy, including those used in the present
study.
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same patient) (Supplementary Table 2). To determine whether this
overexpression was caused by miR-497 and/or miR-195 down-
regulation, we measured transcript levels in our more recent set of
adenomas for four of these 35 mRNA targets and for BCL2 as well
(which was recently identified as a putative miR-195 target17
although it appeared to be downregulated rather than
upregulated in our adenomas) (Supplementary Table 2). None of
the five mRNAs exhibited significantly different expression in the
five adenomas with hypermethylation at the pri-miR-497/195 CpG
island (compared with that observed in the five that were
normally methylated at this locus) (Supplementary Figure 1).
Immunohistochemistry experiments revealed no BCL2 protein
expression in epithelial cells of either normal or adenomatous
colorectal tissues (Supplementary Figure 2), where its expression
was limited almost exclusively to stromal lymphocytes.
DISCUSSION
Our attempt to identify miRNAs whose expression is epigenetically
downregulated in colorectal adenomas revealed that changes of
this type were surprisingly frequent in miRNA-cluster loci that
were monoallelically methylated in normal colorectal mucosa. We
investigated the methylation statuses of CpG islands located
upstream from the TSSs of three of these loci (MEG3, GNAS-AS1
and pri-miR-497-195) in 50 paired samples of colorectal adenoma-
normal mucosa. All three displayed biallelic methylation in a high
percentage of the tumors.
For MEG3 and GNAS-AS1, which are imprinted loci, this tumor-
related hypermethylation of the CpG islands that control their
transcription results in LOI. The link between this phenomenon
and cancer was first noted in 1993, when two laboratories
independently reported biallelic expression of the imprinted gene
IGF2 in Wilms tumors.34,35 Later, IGF2 LOI was also found in normal
and lesional tissues from patients with colorectal cancer,36 and
subsequent studies pointed to hypomethylation-mediated
activation of the normally silent, maternally inherited IGF2 allele
as a risk factor for familial forms of colorectal cancer.37,38
Interestingly, an miRNA gene embedded within IGF2, miR-483,
also appears to be frequently overexpressed in different human
cancers, including those of the colon.39–41 Thus far, KCNQ1OT1 is
the only other gene known to undergo LOI in colorectal cancers,42
but its expression in the precancerous phase of colon
tumorigenesis has not been characterized.
The high frequency of LOI at the MEG3 and GNAS-AS1
miRNA-cluster loci in colorectal adenomas has never been
reported, but LOI at MEG3 has been associated with hematologic
malignancies,43 meningiomas44 and pituitary adenomas.45 Hyper-









































































Figure 2. Pri-miR-497/195 CpG island methylation in paired samples of normal colorectal mucosa and adenomas (six exemplary pairs from the
50 patients) and differential expression of miR-195 and miR-497 in the dysplastic mucosa of adenomas with hypermethylated or normally
methylated pri-miR-497/195 CpG island. (a) COBRA of colorectal adenomas and corresponding normal mucosa samples. Case 9: a normally
methylated sample; the other cases: hypermethylated samples. Arrows indicate TaqaI-digested DNA fragments representing methylated
alleles; and slower-migrating fragments represent undigested, unmethylated DNA. The weak residual band corresponding to TaqaI-
undigested alleles reflects low-level stromal contamination in these endoscopic biopsy specimens, which is absent in the epithelial cell lines
shown in Figure 1c. (b) An example of BGS from a normal/adenoma tissue pair. Each row shows the methylation status of a cloned target
sequence. Circles represent unmethylated (white) and methylated (black) CpG dinucleotides. (c) Relative miR-195 and miR-497 expression in
colorectal adenomas that were normally methylated (n¼ 5) or hypermethylated (n¼ 5) at the pri-miR-497/195 CpG island. These samples were
chosen over 40 other adenomas (7 normally methylated and 33 hypermethylated) because of their high epithelial cell contents reflected by
low Vimentin expression (data not shown). **P¼ 0.0025 (miR-195) and P¼ 0.0087 (miR-497) vs expression in the normally methylated tumors.
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Figure 3. Methylation analysis of regions of GNAS-AS1 (a) and MEG3 (b) that are differentially methylated in adenomas and normal mucosal
samples. Both panels include schematic depictions of the imprinted locus (upper left); examples of COBRA (lower left) and BGS results
(upper right); and expression levels for miRNAs encoded in the locus measured in adenomas in which the locus was hypermethylated or
normally methylated. (Each panel includes representative COBRA results for two adenomas with hypermethylation at the locus and one
normally methylated adenoma.) (a) MiR-296-5p expression was significantly downregulated (P¼ 0.0080) in adenomas with hypermethylation
of the GNAS-AS1 CpG island. (b) Adenomas whose MEG3 CpG island was hypermethylated displayed significantly downregulated miR-154
expression (P¼ 0.0183) and substantial but nonsignificant downregulation of miR-127-3p expression (P¼ 0.0717). ad, adenoma; nm, normal
mucosa.













Figure 4. Epigenetic and genetic variations at the three loci investigated in our 50 adenomas. For each locus, the upper row of squares shows
the methylation status of each tumor (black, hypermethylation; gray, normal methylation; white, hypomethylation), and the lower row
indicates the CNA status (A, amplification; D, deletion; red, loss of the active (unmethylated) allele; green, gain in the number of active
(unmethylated) alleles; white, no CNA).
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detected in over 60% of our colorectal adenomas. However, the
transcriptional regulation of this locus is highly complex
(Figure 3b). Discordance between MEG3 expression and the
expression of certain miRNAs included in this locus has been
reported in pituitary adenomas,45 and a similar picture emerged in
the colorectal adenomas we analyzed. In tumors with LOI at MEG3,
miR-154 and miR-127-3p expression was clearly downregulated
(P¼ 0.01 and P¼ 0.07, respectively) but miR-495 expression was
not. MEG3 encodes over 50 miRNAs,29 so extensive transcriptional
analysis will be necessary to delineate the consequences of
epigenetic alterations at this locus in colorectal adenomas.
Over half of our adenomas displayed LOI at the GNAS-AS1 locus
on chromosome 20q13.3.46 GNAS-AS1 contains imprinted protein-
coding genes and antisense transcripts,47 and imprinting of the
two miRNA genes included in this locus, miR-296 and miR-298, has
also been recently confirmed.26 Underexpression of miR-296 has
been documented in various types of cancers,48,49 including
metastatic lesions from colorectal malignancies,50 but its cause
has not been explored. Our findings indicate that the reduced
expression associated with human colorectal tumorigenesis may
well be due to miR-296 LOI, which appears to be a frequent, early
event in this process that generally stems from epigenetic
alterations (Figure 4).
As for the third gene cluster we tested, miR-497/miR-195 on
chromosome band 17p13.1, its imprinting status is unknown. We
identified the pri-miR-497/195 TSS and found that the CpG island
located upstream from this site is monoallelically methylated in the
normal colon mucosa. In contrast, the island was hypermethylated
in roughly 75% of the colorectal adenomas we tested (Figure 4),
and this change was associated with significant downregulated
expression of both miR-497 and miR-195 (Figure 2c).
This methylation pattern and its similarity to those of GNAS-AS1
and MEG3 (Figure 3) suggest that the pri-miR-497/195 locus might
be a novel imprinted region of the genome. This hypothesis would
have been strengthened by findings of preferential allelic
expression in the lymphoblast cell DNA we analyzed, but it cannot
be rejected solely on the basis of the absence of such evidence.
Indeed, pri-miR-497/195 imprinting might simply be a tissue-
specific phenomenon that occurs in colorectal cells (and possibly
other cells as well) but not in lymphocytes.51 Interestingly, a review
of the COBRA and bisulfite genomic sequencing (BGS) data
published recently by Li et al.52 reveals that this locus also tends to
be monoallelically methylated in normal human breast tissues and
hypermethylated in breast cancers. An alternative hypothesis is
that the phenomenon we observed at pri-miR-497/195 represents
ASM of a nonimprinted locus,16 but this seems less likely for two
reasons: (1) Nonimprinted ASM is usually an individual-specific
phenomenon,16 whereas ASM at pri-miR-497/195 was observed in
all 50 of the normal colorectal mucosal samples we examined; and
(2) the pri-miR-497/195 ASM involves a canonical CpG island—a
typical feature of bona fide imprinting—whereas nonimprinted
ASM generally affects other DNA sequences.53
Regardless of whether it is imprinted or not, the fact that
pri-miR-497/195 is monoallelically methylated in normal colorectal
mucosa and biallelically methylated in most preinvasive tumors of
this tissue is potentially important in terms of the development
and clinical outcome of colorectal cancer. Guo et al.54 showed that
miR-497 exerts tumor-suppressor activity in colorectal cancer by
downregulating the expression of insulin-like growth factor 1.
Downregulation of miR-195 expression has been significantly
linked to increased mortality in patients with this type of cancer.55
Furthermore, Liu et al.17 found that this miRNA is frequently
underexpressed in colorectal cancers (73% of those they
examined) and that it exerts tumor-suppressor effects in colon
cancer cell lines, which are mediated by downregulation of BCL2
expression. The fact that BCL2 mRNA levels were not increased
in the adenomas of our series that exhibited pri-miR-497/195
hypermethylation might reflect differences between the dynamics
of miRNA/target regulation in tissues and those observed in cell
lines, as suggested by our preliminary data on BCL2 protein
expression (Supplementary Figure 2). This finding, however,
together with the lack of negative correlation between transcript
levels of pri-miR-497/195 and those of four other possible miR-497/
195 targets (Supplementary Figure 1), also suggests that the
regulatory effects of pri-miR-497/195 may be exerted mainly
during mRNA translation.
Underexpression of miR-497 and miR-195 was also associated
with DNA copy-number reductions in 93 (71%) of the 131
colorectal cancers analyzed by Guo et al.54, suggesting that
genetic alterations at this locus of chromosome 17p13.1 are
common in advanced-stage colorectal malignancies. These
findings are consistent with our own, which suggest that
epigenetic alterations may precede CNAs at this locus.
Hypermethylation at 17p13.1 was observed in roughly 75% of
our adenomas, but only 10% of these tumors exhibited CNAs. In
contrast, CNAs at this locus were detected in 24.3% of the 833
colorectal cancers included in the Progenetix database.56 The
Progenetix tumors were also frequently characterized by CNAs at
MEG3 (16.4%) and GNAS-A1 (48.1%). These patterns suggest that
early epigenetic alterations might ‘prime’ certain regions for
subsequent loss or gain of genetic material, which—depending
on the genes affected—could have important implications for
tumorigenesis (for example, deletion of the tumor-suppressor
gene TP53, which is located close to miR-497/miR-195 on
chromosome 17p13.1).
In conclusion, our findings reopen the debate on the
importance of LOI in the early stages of colorectal tumorigenesis.
Sporadic colorectal adenomas seem to be characterized by a
relatively high frequency of epigenetic alterations affecting
miRNA-cluster loci that are monoallelically methylated in normal
mucosa, and some of these are known to be imprinted.
Somatically acquired changes of this type could drive transforma-
tion by directly affecting gene expression, but there is also reason
to suspect that they predispose neoplastic cells to genomic
alterations. Additional work is needed to determine whether
pri-miR-497/195 is also, as we suspect, an imprinted locus and to
clarify its mRNA targets.
MATERIALS AND METHODS
Cell lines and tissue samples
Colorectal cancer cell lines (HT29, SW48, GP5D, LS174T, SW620, Colo741,
SW480, HCT116 and SW837) were obtained from the Zurich Cancer
Network’s Cell Line Repository. Cells from this repository have undergone
only a few passages since purchase (from the American Tissue Culture
Collection, Teddington, UK) and are free from mycoplasma infection.
Human colorectal tissues were collected with local ethics committee
approval from patients undergoing colonoscopy in Cremona, Italy (Istituti
Ospitalieri) or Zurich, Switzerland (University Hospital). They were used in
accordance with the Declaration of Helsinki, and each donor provided
written informed consent to sample collection, analysis of data and
publication of the findings. We obtained 50 precancerous lesions
(adenomas), each with a paired sample of normal mucosa from the same
colon segment, 42 cm from the lesion. As these tissues were collected
endoscopically, they were relatively superficial samples with consistently
high epithelial contents.
Comparative studies of the epithelial and stromal components of the
mucosa were carried out on a single, freshly excised specimen of normal
colon from a patient undergoing surgery for diverticulitis. (This donor
provided written informed consent, as described above for patients with
adenomas.) Epithelial crypts and lamina propria were isolated from this
specimen as previously described.57
Genomic DNA and total RNA (including small RNAs) were purified with
commercially available kits. In brief, samples were lysed and homogenized
in RTL Plus Buffer (Qiagen, Basel, Switzerland). The DNA was purified on
spin columns (AllPrep DNA/RNA Mini Kit, Qiagen), and the total RNA was
purified from the AllPrep column flow-through with Mini Spin Columns
(miRCURY RNA Isolation Kit, Exiqon, Vedbaek, Denmark).
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DNA demethylation
HT29 cells were subjected to DNA demethylation treatment the day after
seeding. Cells were grown in medium containing 5-aza-2-deoxycytidine
(Sigma, Buchs SG, Switzerland), which was renewed every 24 h. After 72 h,
they were transferred to medium containing trichostatin A (final
concentration 300 nM) (Sigma) for an additional 16-h growth.
miRNA profiling
miRNA levels were measured in HT29 cells, before and after demethylation,
and in normal colorectal mucosa. We used Exiqon’s MicroRNA Ready-to-
Use PCR, Human panel Iþ II, V2.R, which includes assays for 742 mature
miRNAs and 6 reference genes. The reverse-transcribed RNA (obtained
with the miRCURY LNA Universal RT microRNA PCR, Polyadenylation and
cDNA Synthesis kit from Exiqon) was added to the PCR panels with SYBR
Green Master Mix (Exiqon), and real-time PCR was performed with a Roche
Lightcycler 480 system (Roche, Rotkreutz, Switzerland). miRNAs with a Cp
of440 were classified as nonexpressed. Supplementary Table 3 shows the
LNA PCR primer sets used to quantify individual miRNAs.
5’ RACE
To identify the TSS for pri-miR-497/195, we used 5’ RACE (Ambion’s
FirstChoice RLM-RACE Kit, Ambion, Zug, Switzerland) to analyze 10mg of
total RNA from normal human colonic mucosa. Two specific primers
(Supplementary Table 3) were designed to perform nested-PCR amplifica-
tion of Homo sapiens cDNA FLJ25640 fis, clone STM04823 (GeneBank
Accession AK098506) encompassing the mature forms of miR-497 and miR-
195 (miRBase 19). The miR-RACE amplicon was then cloned (InsTAclone
PCR Cloning kit, Fermentas, St Leon-Rot, Germany) and its specificity
confirmed by sequencing.
Bisulfite conversion, COBRA and BGS
Sodium bisulfite conversion of genomic DNA was done with Qiagen’s
EpiTect Bisulfite kit. COBRA was performed as previously described.8 (See
Supplementary Table 3 for primer sequences and PCR conditions.)
Amplicons were digested with BstUI (GNAS-AS1 and MEG3 CpG islands)
and TaqaI (pri-miR-497/195 5’ CpG island) restriction enzymes (New
England Biolabs, Beverly, MA, USA). For BGS, PCR products were cloned
with the InsTAclone PCR Cloning kit (Fermentas), and individual clones
were sequenced.
qPCR copy-number analysis
Copy numbers at the pri-miR-497/195, MEG3 and GNAS-AS1 loci were
determined with predesigned assays (SABiosciences, Frederick, MD, USA)
and qBiomarker SYBR Green qPCR Mastermix (Qiagen). Gene copy
numbers were averaged with the DDCT method after PCR efficiency
correction.58 The Human Multicopy Reference PCR Assay (SABiosciences,
Assay ID: VPH000-0000000A) was used to normalize input DNA. (Locus-
specific assay IDs are listed in Supplementary Table 3.) Pooled DNA from
three samples of normal colonic mucosa was used as the calibrator, and
assay specificity was validated on DNAs from colon cancer cell lines (HT29,
SW480, SW837, HCT116 and SW48) with known genome-wide copy-
number alteration profiles.59 Loci were classified as amplified or deleted
when their estimated copy numbers were 42.5 or o1.5, respectively.
Analysis of pri-miR-497/195 allelic expression in human white
blood cells
Three lymphoblast cell lines were obtained from the Coriell Institute for
Medical Research. Each line came from a member of the Yoruba
population in Ibadan, Nigeria, who was heterozygous for the SNP
rs412999 (dbSNP ID: 412999) in the pri-miR-497/195 locus. Individual
subcloned PCR products from retrotranscribed RNA isolated from these
cells were sequenced to assess differential allelic expression of pri-miR-497/
195. Primers used for genotyping are listed in Supplementary Table 3.
Quantitative real-time reverse-transcription PCR
First-strand cDNA synthesis, qPCR and relative quantification of transcript
levels were performed as previously described.8 All primer sequences are
reported in Supplementary Table 3.
BCL2 immunohistochemistry
Immunostaining was performed with BCL2 antibody (no. 790-4464;
Ventana, Tucson, AZ, USA) as described elsewhere.7
Statistical analysis
Two-tailed P-values were calculated with the unpaired t-test to compare
differences between sample miRNA and mRNA expression means.
Analyses were performed using the GraphPad Prism 5.0 statistical software
package for Macintosh computers (GraphPad, La Jolla, CA, USA).
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